"Our hypothesis is that ONCONASE®, with its proven affinity for rapidly-dividing cancerous cells, inhibition of protein synthesis and induction of apoptosis, will block the formation of tumors and therefore arrest or eradicate the disease in its early stages without the need for surgery," stated Dr. Carbone.
"As such, swift identification of at-risk families exposed to asbestos and erionite, which are clearly linked to the onset of mesothelioma, early diagnosis of the disease and treatment with ONCONASE® will be among the key cornerstones of this exciting program."
ONCONASE® (ranpirnase) is Alfacell Corporation’s lead investigational drug candidate that is currently being evaluated in several studies, including a Phase IIIb trial for malignant mesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC).
Read more at Alfacell Corp. News.
.jpg)
Comment Preview